Hypromellose: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
No edit summary
 
(6 intermediate revisions by the same user not shown)
Line 1: Line 1:
{{DrugProjectFormSinglePage
{{DrugProjectFormSinglePage
|authorTag={{RB}}
|authorTag={{RB}}
|OTC=Yes
|genericName=Hypromellose
|genericName=Hypromellose
|aOrAn=a
|aOrAn=a
|drugClass=ophthalmic solution
|drugClass=ophthalmic solution
|indicationType=treatment
|indicationType=treatment
|indication=dryness of the eye and prevent further irritation.
|indication=[[dryness of the eye]] and prevent further irritation
|adverseReactions=eye pain, changes in vision.
|adverseReactions=[[eye pain]], [[changes in vision]]
|blackBoxWarningTitle=<b><span style="color:#FF0000;">TITLE</span></b>
|blackBoxWarningTitle=<b><span style="color:#FF0000;">TITLE</span></b>
|blackBoxWarningBody=<i><span style="color:#FF0000;">Condition Name:</span></i> (Content)
|blackBoxWarningBody=<i><span style="color:#FF0000;">Condition Name:</span></i> (Content)
|fdaLIADAdult=*Relieves dryness of the eye.
|fdaLIADAdult=*Relieves [[dryness of the eye]].
*Temporarily relieves discomfort due to minor irritations of the eye or from exposure to wind and sun.
*Temporarily relieves discomfort due to minor irritations of the eye or from exposure to wind and sun.
*As a protectant against further irritation.
*As a protectant against further irritation.
Line 36: Line 37:
* If you experience eye pain, changes in vision, continued redness or irritation of the eye, or if the condition worsens or persists for more than 72 hours, discontinue use and consult a doctor.
* If you experience eye pain, changes in vision, continued redness or irritation of the eye, or if the condition worsens or persists for more than 72 hours, discontinue use and consult a doctor.


====Precautions====
* Description


<!--Adverse Reactions-->
<!--Adverse Reactions-->


<!--Clinical Trials Experience-->
<!--Clinical Trials Experience-->
|clinicalTrials=* eye pain
|clinicalTrials=* [[eye pain]]
* changes in vision
* [[changes in vision]]
|postmarketing=There is limited information regarding <i>Postmarketing Experience</i> of {{PAGENAME}} in the drug label.
|postmarketing=There is limited information regarding <i>Postmarketing Experience</i> of {{PAGENAME}} in the drug label.
|useInPregnancyAUS=There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of {{PAGENAME}} in women who are pregnant.
|useInPregnancyAUS=There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of {{PAGENAME}} in women who are pregnant.
Line 59: Line 57:


<!--Administration and Monitoring-->
<!--Administration and Monitoring-->
|administration=* Opthalmic solution
|administration=* Ophthalmic solution
|monitoring=There is limited information regarding <i>Monitoring</i> of {{PAGENAME}} in the drug label.
|monitoring=There is limited information regarding <i>Monitoring</i> of {{PAGENAME}} in the drug label.
|IVCompat=There is limited information regarding <i>IV Compatibility</i> of {{PAGENAME}} in the drug label.
|IVCompat=There is limited information regarding <i>IV Compatibility</i> of {{PAGENAME}} in the drug label.
Line 67: Line 65:


<!--Drug box 2-->
<!--Drug box 2-->
|drugBox=<!--Mechanism of Action-->
|drugBox={{Chembox2
| verifiedrevid = 451585076
| ImageFile = Hypromellose Wiki Structure.png
| ImageSize = 200px
| IUPACName =
| OtherNames = Hydroxypropyl methylcellulose; hydroxypropyl methyl cellulose; HPMC; E464
| Section1 = {{Chembox Identifiers
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 21241863
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 36SFW2JZ0W
| InChI = 1/C36H70O19.C20H38O11/c1-19(37)9-45-17-27-29(47-11-21(3)39)31(48-12-22(4)40)34(51-15-25(7)43)36(54-27)55-30-28(18-46-10-20(2)38)53-35(52-16-26(8)44)33(50-14-24(6)42)32(30)49-13-23(5)41;1-21-9-11-13(23-3)15(24-4)18(27-7)20(30-11)31-14-12(10-22-2)29-19(28-8)17(26-6)16(14)25-5/h19-44H,9-18H2,1-8H3;11-20H,9-10H2,1-8H3/t19?,20?,21?,22?,23?,24?,25?,26?,27-,28-,29-,30-,31+,32+,33-,34-,35-,36+;11-,12-,13-,14-,15+,16+,17-,18-,19-,20+/m11/s1
| InChIKey = PUSNGFYSTWMJSK-GSZQVNRLBE
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C36H70O19.C20H38O11/c1-19(37)9-45-17-27-29(47-11-21(3)39)31(48-12-22(4)40)34(51-15-25(7)43)36(54-27)55-30-28(18-46-10-20(2)38)53-35(52-16-26(8)44)33(50-14-24(6)42)32(30)49-13-23(5)41;1-21-9-11-13(23-3)15(24-4)18(27-7)20(30-11)31-14-12(10-22-2)29-19(28-8)17(26-6)16(14)25-5/h19-44H,9-18H2,1-8H3;11-20H,9-10H2,1-8H3/t19?,20?,21?,22?,23?,24?,25?,26?,27-,28-,29-,30-,31+,32+,33-,34-,35-,36+;11-,12-,13-,14-,15+,16+,17-,18-,19-,20+/m11/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = PUSNGFYSTWMJSK-GSZQVNRLSA-N
| CASNo_Ref = {{cascite|correct|CAS}}
| CASNo = 9004-65-3
| PubChem =
| ATCCode_prefix = S01
| ATCCode_suffix = KA02
| SMILES = }}
| Section2 = {{Chembox Properties
| Formula = variable
| MolarMass = variable
| Appearance =
| Density =
| MeltingPt =
| BoilingPt =
| Solubility = }}
| Section3 = {{Chembox Hazards
| MainHazards =
| FlashPt =
| Autoignition = }}
}}
|PD=There is limited information regarding <i>Pharmacodynamics</i> of {{PAGENAME}} in the drug label.
|PD=There is limited information regarding <i>Pharmacodynamics</i> of {{PAGENAME}} in the drug label.


Line 98: Line 131:
<!--Brand Names-->
<!--Brand Names-->
|brandNames=* GenTeal®<ref>{{Cite web | title = Hypromellose | url = http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3c4ea323-2407-4f9d-b44f-eebf127924ba }}</ref>
|brandNames=* GenTeal®<ref>{{Cite web | title = Hypromellose | url = http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3c4ea323-2407-4f9d-b44f-eebf127924ba }}</ref>
<!--Look-Alike Drug Names-->
|drugShortage=
|drugShortage=
}}
{{PillImage
|fileName=No image.jpg
}}
{{LabelImage
}}
}}
<!--Pill Image-->
<!--Pill Image-->

Latest revision as of 15:28, 24 February 2015

Hypromellose
Adult Indications & Dosage
Pediatric Indications & Dosage
Contraindications
Warnings & Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Administration & Monitoring
Overdosage
Pharmacology
Clinical Studies
How Supplied
Images
Patient Counseling Information
Precautions with Alcohol
Brand Names
Look-Alike Names

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Rabin Bista, M.B.B.S. [2]

Disclaimer

WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.
NOTE: Most over the counter (OTC) are not reviewed and approved by the FDA. However, they may be marketed if they comply with applicable regulations and policies. FDA has not evaluated whether this product complies.

Overview

Hypromellose is a ophthalmic solution that is FDA approved for the treatment of dryness of the eye and prevent further irritation. Common adverse reactions include eye pain, changes in vision.

Adult Indications and Dosage

FDA-Labeled Indications and Dosage (Adult)

  • Relieves dryness of the eye.
  • Temporarily relieves discomfort due to minor irritations of the eye or from exposure to wind and sun.
  • As a protectant against further irritation.

Dosage

  • Put 1 or 2 drops in the affected eye(s) as needed.

Off-Label Use and Dosage (Adult)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Hypromellose in adult patients.

Non–Guideline-Supported Use

There is limited information regarding Off-Label Non–Guideline-Supported Use of Hypromellose in adult patients.

Pediatric Indications and Dosage

FDA-Labeled Indications and Dosage (Pediatric)

There is limited information regarding FDA-Labeled Use of Hypromellose in pediatric patients.

Off-Label Use and Dosage (Pediatric)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Hypromellose in pediatric patients.

Non–Guideline-Supported Use

There is limited information regarding Off-Label Non–Guideline-Supported Use of Hypromellose in pediatric patients.

Contraindications

There is limited information regarding Hypromellose Contraindications in the drug label.

Warnings

  • For external use only.
  • Do not use if sealed bottle tip is broken or punctured.
  • If solution changes color or becomes cloudy, do not use.

When using this product

  • To avoid contamination, do not touch tip of container to any surface.
  • Replace cap after using.

Stop use and ask a physician

  • If you experience eye pain, changes in vision, continued redness or irritation of the eye, or if the condition worsens or persists for more than 72 hours, discontinue use and consult a doctor.

Adverse Reactions

Clinical Trials Experience

Postmarketing Experience

There is limited information regarding Postmarketing Experience of Hypromellose in the drug label.

Drug Interactions

There is limited information regarding Hypromellose Drug Interactions in the drug label.

Use in Specific Populations

Pregnancy

Pregnancy Category (FDA): There is no FDA guidance on usage of Hypromellose in women who are pregnant.
Pregnancy Category (AUS): There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Hypromellose in women who are pregnant.

Labor and Delivery

There is no FDA guidance on use of Hypromellose during labor and delivery.

Nursing Mothers

There is no FDA guidance on the use of Hypromellose with respect to nursing mothers.

Pediatric Use

There is no FDA guidance on the use of Hypromellose with respect to pediatric patients.

Geriatic Use

There is no FDA guidance on the use of Hypromellose with respect to geriatric patients.

Gender

There is no FDA guidance on the use of Hypromellose with respect to specific gender populations.

Race

There is no FDA guidance on the use of Hypromellose with respect to specific racial populations.

Renal Impairment

There is no FDA guidance on the use of Hypromellose in patients with renal impairment.

Hepatic Impairment

There is no FDA guidance on the use of Hypromellose in patients with hepatic impairment.

Females of Reproductive Potential and Males

There is no FDA guidance on the use of Hypromellose in women of reproductive potentials and males.

Immunocompromised Patients

There is no FDA guidance one the use of Hypromellose in patients who are immunocompromised.

Administration and Monitoring

Administration

  • Ophthalmic solution

Monitoring

There is limited information regarding Monitoring of Hypromellose in the drug label.

IV Compatibility

There is limited information regarding IV Compatibility of Hypromellose in the drug label.

Overdosage

There is limited information regarding Chronic Overdose of Hypromellose in the drug label.

Pharmacology

Template:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox E numberTemplate:Chembox Supplement
Template:Chembox header2 | Hypromellose
Identifiers
ChemSpider
ECHA InfoCard Lua error in Module:Wikidata at line 879: attempt to index field 'wikibase' (a nil value). Lua error in Module:Wikidata at line 879: attempt to index field 'wikibase' (a nil value).
UNII
Properties
variable
Molar mass variable
Template:Chembox header2 | Except where noted otherwise, data are given for
materials in their standard state
(at 25 °C, 100 kPa)
Infobox disclaimer and references

Mechanism of Action

There is limited information regarding Hypromellose Mechanism of Action in the drug label.

Structure

There is limited information regarding Hypromellose Structure in the drug label.

Pharmacodynamics

There is limited information regarding Pharmacodynamics of Hypromellose in the drug label.

Pharmacokinetics

There is limited information regarding Pharmacokinetics of Hypromellose in the drug label.

Nonclinical Toxicology

There is limited information regarding Nonclinical Toxicology of Hypromellose in the drug label.

Clinical Studies

There is limited information regarding Clinical Studies of Hypromellose in the drug label.

How Supplied

There is limited information regarding Hypromellose How Supplied in the drug label.

Storage

  • Store at room temperature 15°-30°C (59°-86°F).
  • Do not freeze.
  • Keep box for complete information.

Images

Drug Images

{{#ask: Page Name::Hypromellose |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}

Package and Label Display Panel

Principal display panel

Ingredients and Appearance

{{#ask: Label Page::Hypromellose |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}

Patient Counseling Information

  • When using this product do not touch tip of container to any surface. Replace cap after using.
  • Stop use and ask a doctor if you experience any of the following:
  • eye pain
  • changes in vision
  • continued redness or irritation of the eye
  • condition worsens or persists for more than 72 hours
  • If swallowed, get medical help or contact a Poison Control Center right away.

Precautions with Alcohol

  • Alcohol-Hypromellose interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.

Brand Names

Look-Alike Drug Names

There is limited information regarding Hypromellose Look-Alike Drug Names in the drug label.

Drug Shortage Status

Price

References

The contents of this FDA label are provided by the National Library of Medicine.

  1. ↑ "Hypromellose".
Retrieved from "https://www.wikidoc.org/index.php?title=Hypromellose&oldid=1072855"